Biotechnology momentum in Canada needs infusion of talent and anchor firms, say industry reps
Canada has several prominent life science firms, but none can be considered an anchor company, according to a report by the adMare Institute released in late 2023.
Senate aims to serve up pharmacare for Thanksgiving
The Senate Social Affairs, Science, and Technology Committee will have just four weeks to study the pharmacare legislation before its scheduled third reading vote on Oct. 10.
Focus on pharmacare
Plus, Marc Miller announces new measures for temporary residents.
Canada needs to catch up in the biotech sector
Currently, our scientists have to look outside of the country to take their work to the next level, which means that Canada is not benefitting fully from Canadian ideas.
Unlocking Canada’s greatest economic potential: life sciences
The time has come for us to commit to life sciences as a driver for Canada’s economy with the knowledge that this sector can help solve some of our biggest societal challenges.
Politics: the overlooked determinant of children’s health
The commitment of elected officials to prioritize our children’s well-being determines how and if policies will be enacted or sustained beyond a single election cycle.
Public servants sound off over new return-to-office mandate, while union faces heat over its ‘Buy Nothing’ campaign
Public service union walks back calls to boycott downtown Ottawa business.
Wake up, Canada: there’s no health or wealth without proper funding of health research
Canada provides significantly more in annual subsidies for the fossil fuel industry than it does to conduct the research that underpins the health and wealth of Canadians.
Bloc to push feds to back MP’s seniors supports bill this fall
There are 52 private members’ bills currently before Parliament, and Conservative MP Randy Hoback is first in line on the order of precedence.
The NDP-backed pharmacare plan is a corporate handout as written
The real problem with this signature legislation of the NDP-Liberal agreement is that it will not bring medicines within Canada’s publicly funded health system.
